<DOC>
	<DOCNO>NCT03039192</DOCNO>
	<brief_summary>The purpose study evaluate efficacy intranasal esketamine 84 milligram ( mg ) compare intranasal placebo addition comprehensive standard care reduce symptom Major Depressive Disorder ( MDD ) , include suicidal ideation , participant assess imminent risk suicide , measure change baseline Montgomery-Asberg Depression Rating Scale ( MADRS ) total score 24 hour post first dose .</brief_summary>
	<brief_title>A Study Efficacy Safety Intranasal Esketamine Rapid Reduction Symptoms Major Depressive Disorder , Adults Imminent Risk Suicide</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , double-blind ( neither researcher participant know treatment participant receiving ) , placebo-controlled ( inactive substance contains drug ) compare clinical trial drug test drug real effect ) , multicenter ( one hospital study team work medical research study ) study . Study enroll participant suicidal ideation assess imminent risk suicide . The study consist screen evaluation perform within 48 hour prior Day 1 intranasal dose immediately follow 25-day double-blind treatment phase ( Day 1 25 ) , 65 day follow-up phase ( Day 26 Day 90 ) . The total study duration subject approximately 13 week . Participants ' safety evaluate throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<criteria>Participant must meet Diagnostic Statistical Manual Mental Disorders ( 5th edition ) ( DSM5 ) diagnostic criterion Major Depressive Disorder ( MDD ) , without psychotic feature , base upon clinical assessment confirm Mini International Psychiatric Interview ( MINI ) In physician 's opinion , acute psychiatric hospitalization clinically warrant due participant 's imminent risk suicide Participants must current suicidal ideation intent , confirm `` Yes '' response Question B3 [ Think ( even momentarily ) harm hurt injuring : least intent awareness might die result ; think suicide ( ie , kill ) ? ] AND Question B10 [ Intend act thought kill ? ] obtain MINI . Note : response B3 must refer present , whereas response B10 may reflect past 24 hour . If screening period longer 24 hour , assessment B3 B10 MINI must repeat prior randomization confirm eligibility Participant Montgomery Asberg Depression Rating Scale ( MADRS ) total score great ( &gt; ) 28 predose Day 1 As part standard care treatment , participant agrees hospitalize voluntarily recommended period 5 day randomization ( may shorter longer clinically warranted investigator 's opinion ) take prescribed noninvestigational antidepressant therapy ( y ) least duration doubleblind treatment phase ( Day 25 ) Participant comfortable selfadministration intranasal medication able follow instruction provide Participant current DSM5 diagnosis bipolar ( related disorder ) , antisocial personality disorder , obsessive compulsive disorder Participant currently meet DSM5 criterion borderline personality disorder . Participant meeting full DSM5 criterion borderline personality disorder exhibit recurrent suicidal gesture , threat , selfmutilating behavior also exclude Participant current clinical diagnosis autism , dementia , intellectual disability Participant current prior DSM5 diagnosis psychotic disorder , MDD psychotic feature Participant history moderate severe substance alcohol use disorder , accord DSM5 criterion , except nicotine caffeine , within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>